TY - JOUR
T1 - Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy
T2 - a randomized repeat-treatment study
AU - the Dysport in PUL study group
AU - Delgado, Mauricio R.
AU - Tilton, Ann
AU - Carranza-Del Río, Jorge
AU - Dursun, Nigar
AU - Bonikowski, Marcin
AU - Aydin, Resa
AU - Maciag-Tymecka, Iwona
AU - Oleszek, Joyce
AU - Dabrowski, Edward
AU - Grandoulier, Anne Sophie
AU - Picaut, Philippe
AU - Renders, Anne
AU - Kraus, Josef
AU - Minks, Eduard
AU - Givon, Uri
AU - Sadaka, Yair
AU - Weigl, Daniel
AU - Fattal-Valevski, Aviva
AU - Ben-Pazi, Hilla
AU - Gonzalez, Jose Alberto Moreno
AU - Perez Flores, Elsa Maria Ivon
AU - Jozwiak, Marek
AU - Garreta Figuera, Roser
AU - Alonso Curco, Xenia
AU - Melendez Plumed, Mar
AU - Peker, Ozlen
AU - Phillips, John P.
AU - Revivo, Gadi
AU - Evans, Sarah H.
AU - Wright, Edward A.
AU - Wilson, Jenny Lupovici
AU - Kim, Heakyung
AU - Aylward, Shawn
AU - Gormley, Mark E.
N1 - Publisher Copyright:
© 2020 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press
PY - 2021/5
Y1 - 2021/5
N2 - Aim: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). Method: This was a double-blind, repeat-cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home-exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. Results: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment-related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). Interpretation: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. What this paper adds: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year.
AB - Aim: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). Method: This was a double-blind, repeat-cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home-exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. Results: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment-related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). Interpretation: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. What this paper adds: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year.
UR - http://www.scopus.com/inward/record.url?scp=85096717960&partnerID=8YFLogxK
U2 - 10.1111/dmcn.14733
DO - 10.1111/dmcn.14733
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33206382
AN - SCOPUS:85096717960
SN - 0012-1622
VL - 63
SP - 592
EP - 600
JO - Developmental Medicine and Child Neurology
JF - Developmental Medicine and Child Neurology
IS - 5
ER -